Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Endometrial Carcinoma

Treatments: Drug: Fulvestrant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00334295

9238GR/0002

Details and patient eligibility

About

The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.

Enrollment: 35 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed, recurrent or metastatic endometrial carcinoma
• Postmenopausal
• Hormonreceptor positive

Exclusion criteria

• Pre-treatment with Fulvestrant
• Previous endocrine therapy of the endometrial carcinoma
• Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)